Paper Review Records
All Paper Review Records
14 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
FABP4+ macrophages promote glycolysis in lung cancer progression through the TNF-α–MYC pathway
Lingwei Liu; Weibin Shu; Chuanxi Wang; Qiang Wen; Hongchang Shen; Qiang Li; Keying CheShow moreShow less
1. Department of Nuclear Medicine, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, China; 2. Tumor Research and Therapy Center, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, ChinaShow moreShow less
Dendritic cells enhance tebentafusp-mediated T cell effector responses
Manuel Wiesinger; Anne Petzold; Markus Luber; Philipp Hilgendorf; Andreas Wild; Markus Vincent Heppt; Beatrice Schuler‐Thurner; Kilian Schober; Carola Berking; Elias A. T. KochShow moreShow less
1. Friedrich-Alexander-Universität Erlangen-Nürnberg; 2. Universitätsklinikum Erlangen; 3. Comprehensive Cancer Center ErlangenShow moreShow less
Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis
K. E. Blethen; C. P. Wolford; G. L. Pecar; T. A. Arsiwala; E. Adjeroh; L. P. Dykstra; B. N. Kielkowski; P. R. LockmanShow moreShow less
1. Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, USA; 2. Rockefeller Neuroscience Institute, West Virginia University, Morgantown, USAShow moreShow less
Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma
Feihua Chen; Mouchun Gong; Dengcheng Weng; Zhaoqing Jin; Guofeng Han; Ziqiang Yang; Junjun Han; Jianjiang WangShow moreShow less
1. Department of General Surgery, Hangzhou Medical College Affiliated Lin’an People’s Hospital, Hangzhou, ChinaShow moreShow less
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment
Joanna Baginska; Allison Nau; Ilana Gomez Diaz; Anita Giobbie-Hurder; Jason Weirather; Juliana Vergara; Charlotte Abrecht; Margaret Hallisey; Jenna Dennis; Mariano Severgnini; Julia Huezo; Isabella Marciello; Osama Rahma; Michael Manos; Andrew S. Brohl; Philippe L. Bedard; Daniel J. Renouf; Elad Sharon; Howard Streicher; Patrick A. Ott; Elizabeth I. Buchbinder; F. Stephen HodiShow moreShow less
1. Department of Medical Oncology, Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, USA; 2. Department of Data Science, Dana-Farber Cancer Institute, Boston, USA; 3. Sarcoma Department and Cutaneous Oncology, Moffitt Cancer Center, Tampa, USA; 4. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; 5. Cancer and Department of Medicine, University of British Columbia, Vancouver, Canada; 6. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, USAShow moreShow less
Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice
Akashdip Singh; Eline T. A. M. Mommers-Elshof; Saskia V. Vijver; J. H. Marco Jansen; Susanne Gonder; Robert Jan Lebbink; Dominique Bihan; Richard W. Farndale; Louis Boon; Solomon Langermann; Jeanette H. W. Leusen; Dallas Flies; Linde Meyaard; M. Ines Pascoal RamosShow moreShow less
1. Centre for Translational Immunology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands; 2. Oncode Institute, Utrecht, The Netherlands; 3. Department of Biochemistry, University of Cambridge, Cambridge, UK; 4. JJP Biologics, Warsaw, Poland; 5. Nextcure, Beltsville, USAShow moreShow less
FAQ
How long does CANCER IMMUNOLOGY IMMUNOTHERAPY take to review a manuscript?
As of 2026-11-19, CrushSCI has 14 complete review records for CANCER IMMUNOLOGY IMMUNOTHERAPY. The fastest paper went from submission to acceptance in 34 days (Coordination of anti-CTLA-4 with whole-brain radiation therapy decreases tumor burden during treatment in a novel syngeneic model of lung cancer brain metastasis, received 2023-10-03, accepted 2023-11-06); the slowest took 176 days. The average is 85.9 days and the median is 64 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
